Status:
UNKNOWN
Personalizing Colorectal Cancer Medicine (ImmuCol2)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Colorectal cancers are the leading cancers for both sexes combined. They represent 15-20% of all cancers. This cancer has a severe prognosis, the survival rate at 5 years is around 55% and in France i...
Detailed Description
The project aims: (i) to combine at time of diagnosis the immunoscore with parameters related to the patient, its tumor and the associated microenvironment (ii) to detect events occurring during the ...
Eligibility Criteria
Inclusion
- Adult patient with newly diagnosed colon cancer
- Patient with signed informed consent
- Patient follow-up during the first three years made in the recruiting center
Exclusion
- Adjuvant treatment (chemotherapy) started at the time of inclusion
Key Trial Info
Start Date :
March 11 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT02274753
Start Date
March 11 2015
End Date
December 31 2021
Last Update
October 12 2021
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital de Besançon (CHU)
Besançon, France, 25000
2
Hopital Avicenne
Bobigny, France, 93000
3
CHU de Bordeaux
Bordeaux, France, 33000
4
Institut Bergonié Bordeaux
Bordeaux, France, 33000